Skip to main content
Premium Trial:

Request an Annual Quote

Variagenics Reports Higher Losses, Tiny Revenues for Q2

NEW YORK, Aug. 6-Variagenics' losses nearly doubled and its revenues dwindled to only $200,000 in the second quarter of 2002, the company said today.


The slide was substantial from the second quarter of 2001, when the company reported $900,000 in revenues.


Net losses for the quarter, including a nearly $2 million restructuring charge and $1.3 million in equity compensation, totaled $9.8 million or 42 cents per share. In the equivalent period of 2001, Variagenics reported a loss of $5.6 million or 24 cents per share.


R&D  expenses for the period climbed from $4 million in the second quarter of last year to $5.2 million in the equivalent period this year.


The company said it held $64 million in cash, cash equivalents and short-term marketable securities as of June 30.


Variagenics expects that its restructuring, which was put in place in May 2002, will lower its net cash burn rate to about $4 million per quarter by the fourth quarter of this year.


For more information, see the press release.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.